Loading...
OTCM
AMPE
Market cap0kUSD
Apr 28, Last price  
0.00USD
1D
-96.32%
1Q
60.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Ampio Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.98%
Rev. gr., 5y
35.72%
Revenues
0k
0000018,75050,00050,00076,7871,162,46200000000
Net income
-9m
L+1.95%
-1,004-31,995-31,881-26,051-8,053,395-18,359,234-11,593,045-24,008,558-38,125,415-32,010,242-19,163,629-51,891,94533,986,166-8,684,000-16,498,000-12,485,000-8,467,000-8,632,000
CFO
-9m
L-59.47%
-990-18,346-37,774-21,380-2,628,331-9,131,662-9,715,163-19,133,157-30,740,583-26,444,110-14,624,972-11,407,947-12,138,023-15,383,000-14,729,000-14,089,000-21,128,000-8,564,000

Profile

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
URL
https://ampiopharma.com/
IPO date
May 19, 2011
Employees
8
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
9,768
22,461
Unusual Expense (Income)
NOPBT
(9,768)
(22,461)
NOPBT Margin
Operating Taxes
(7,870)
Tax Rate
NOPAT
(9,768)
(14,591)
Net income
(8,632)
1.95%
(8,467)
-32.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
98
(32)
BB yield
-5.90%
0.95%
Debt
Debt current
548
340
Long-term debt
274
888
Deferred revenue
Other long-term liabilities
333
Net debt
(3,267)
(11,425)
Cash flow
Cash from operating activities
(8,564)
(21,128)
CAPEX
Cash from investing activities
Cash from financing activities
(111)
FCF
(9,509)
(11,657)
Balance
Cash
4,089
12,653
Long term investments
Excess cash
4,089
12,653
Stockholders' equity
(242,527)
(233,937)
Invested Capital
246,435
246,521
ROIC
ROCE
EV
Common stock shares outstanding
810
754
Price
2.05
-54.48%
4.50
-97.37%
Market cap
1,661
-51.07%
3,394
-97.04%
EV
(1,606)
(8,031)
EBITDA
(9,646)
(21,413)
EV/EBITDA
0.17
0.38
Interest
7,870
Interest/NOPBT